BRPI1006901A2 - método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangue - Google Patents
método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangueInfo
- Publication number
- BRPI1006901A2 BRPI1006901A2 BRPI1006901A BRPI1006901A BRPI1006901A2 BR PI1006901 A2 BRPI1006901 A2 BR PI1006901A2 BR PI1006901 A BRPI1006901 A BR PI1006901A BR PI1006901 A BRPI1006901 A BR PI1006901A BR PI1006901 A2 BRPI1006901 A2 BR PI1006901A2
- Authority
- BR
- Brazil
- Prior art keywords
- sicam
- kit
- patient
- testing
- levels
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09305044 | 2009-01-20 | ||
| EP09305294 | 2009-04-07 | ||
| PCT/EP2010/050532 WO2010084100A1 (en) | 2009-01-20 | 2010-01-18 | Soluble icam-1 as biomarker for prediction of therapeutic response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006901A2 true BRPI1006901A2 (pt) | 2016-02-16 |
Family
ID=42028081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006901A BRPI1006901A2 (pt) | 2009-01-20 | 2010-01-18 | método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangue |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20110312525A1 (enExample) |
| EP (1) | EP2382474B1 (enExample) |
| JP (1) | JP5379243B2 (enExample) |
| KR (1) | KR20110116016A (enExample) |
| CN (1) | CN102292638B (enExample) |
| AU (1) | AU2010206195B2 (enExample) |
| BR (1) | BRPI1006901A2 (enExample) |
| CA (1) | CA2749192A1 (enExample) |
| CO (1) | CO6390020A2 (enExample) |
| CR (1) | CR20110438A (enExample) |
| DK (1) | DK2382474T3 (enExample) |
| ES (1) | ES2536747T3 (enExample) |
| HR (1) | HRP20150470T1 (enExample) |
| HU (1) | HUE025015T2 (enExample) |
| IL (1) | IL213098A (enExample) |
| MX (1) | MX2011007386A (enExample) |
| NZ (1) | NZ593749A (enExample) |
| PL (1) | PL2382474T3 (enExample) |
| PT (1) | PT2382474E (enExample) |
| SG (2) | SG196837A1 (enExample) |
| TW (1) | TWI440854B (enExample) |
| WO (1) | WO2010084100A1 (enExample) |
| ZA (1) | ZA201105271B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103175959B (zh) * | 2013-02-28 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破免疫层析试纸的制备方法 |
| CN103235134B (zh) * | 2013-05-08 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破的免疫层析试纸及其制备方法 |
| CN103698537A (zh) * | 2014-01-06 | 2014-04-02 | 天津医科大学总医院 | 定量检测人血清可溶性细胞间粘附分子-1的化学发光免疫分析试剂盒及检测方法 |
| CN112292142A (zh) * | 2018-03-06 | 2021-01-29 | Pepvax公司 | 核酸分子及其使用方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| FR2643817B1 (fr) | 1989-03-06 | 1993-12-17 | Transgene Sa | Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus |
| FR2602790B1 (fr) * | 1986-08-13 | 1990-06-01 | Transgene Sa | Expression d'un antigene specifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement preventif ou curatif de la tumeur correspondante |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US6054438A (en) | 1987-01-07 | 2000-04-25 | Imperial Cancer Research Technology Limited | Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin |
| EP0289949B1 (en) | 1987-05-04 | 1995-10-04 | Dana Farber Cancer Institute | Intercellular adhesion molecules, and their binding ligands |
| FR2632863B2 (fr) | 1987-10-29 | 1990-08-31 | Transgene Sa | Virus du fowlpox recombinant et vaccins derives de ces virus |
| CA2008368C (en) | 1989-01-24 | 2003-04-08 | Jeffrey Greve | Soluble molecule related to but distinct from icam-1 |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| FR2668064B1 (fr) | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
| AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US5698443A (en) | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
| US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| WO1998004727A1 (en) | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| FR2751879B1 (fr) | 1996-07-30 | 1998-10-30 | Transgene Sa | Composition pharmaceutique contre les tumeurs et infections a papillomavirus |
| AU727308B2 (en) | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
| US20020037274A1 (en) | 1998-10-26 | 2002-03-28 | Angelica Williams | Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants |
| FR2787465A1 (fr) | 1998-12-21 | 2000-06-23 | Transgene Sa | Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes |
| ES2220448T3 (es) | 1999-02-04 | 2004-12-16 | Geron Corporation | Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa. |
| ATE332364T1 (de) | 1999-02-22 | 2006-07-15 | Transgene Sa | Verfahren zur gewinnung von purifizierter virenzuammensetzung |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US7001596B1 (en) | 1999-11-15 | 2006-02-21 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| AUPQ520800A0 (en) | 2000-01-21 | 2000-02-17 | Alfred Hospital | Prime-boost vaccination strategy |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| MXPA05004588A (es) | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c. |
| FR2855758B1 (fr) | 2003-06-05 | 2005-07-22 | Biomerieux Sa | Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique |
| FR2862648B1 (fr) | 2003-11-21 | 2006-02-03 | Biomerieux Sa | Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c |
| US7381536B2 (en) | 2005-03-01 | 2008-06-03 | Gurbel Paul A | Assessment of cardiac health and thrombotic risk in a patient |
-
2010
- 2010-01-18 SG SG2014004030A patent/SG196837A1/en unknown
- 2010-01-18 US US13/145,336 patent/US20110312525A1/en not_active Abandoned
- 2010-01-18 HU HUE10704115A patent/HUE025015T2/en unknown
- 2010-01-18 HR HRP20150470TT patent/HRP20150470T1/hr unknown
- 2010-01-18 PT PT107041154T patent/PT2382474E/pt unknown
- 2010-01-18 KR KR1020117016841A patent/KR20110116016A/ko not_active Abandoned
- 2010-01-18 PL PL10704115T patent/PL2382474T3/pl unknown
- 2010-01-18 AU AU2010206195A patent/AU2010206195B2/en not_active Ceased
- 2010-01-18 BR BRPI1006901A patent/BRPI1006901A2/pt not_active Application Discontinuation
- 2010-01-18 WO PCT/EP2010/050532 patent/WO2010084100A1/en not_active Ceased
- 2010-01-18 DK DK10704115T patent/DK2382474T3/en active
- 2010-01-18 ES ES10704115.4T patent/ES2536747T3/es active Active
- 2010-01-18 NZ NZ593749A patent/NZ593749A/xx not_active IP Right Cessation
- 2010-01-18 CN CN201080004940.8A patent/CN102292638B/zh not_active Expired - Fee Related
- 2010-01-18 JP JP2011545757A patent/JP5379243B2/ja not_active Expired - Fee Related
- 2010-01-18 CA CA2749192A patent/CA2749192A1/en not_active Abandoned
- 2010-01-18 EP EP10704115.4A patent/EP2382474B1/en not_active Not-in-force
- 2010-01-18 SG SG2011052404A patent/SG173065A1/en unknown
- 2010-01-18 MX MX2011007386A patent/MX2011007386A/es active IP Right Grant
- 2010-01-20 TW TW099101520A patent/TWI440854B/zh not_active IP Right Cessation
-
2011
- 2011-05-24 IL IL213098A patent/IL213098A/en not_active IP Right Cessation
- 2011-07-18 ZA ZA2011/05271A patent/ZA201105271B/en unknown
- 2011-07-19 CO CO11090083A patent/CO6390020A2/es not_active Application Discontinuation
- 2011-08-17 CR CR20110438A patent/CR20110438A/es not_active Application Discontinuation
-
2013
- 2013-05-23 US US13/900,869 patent/US20140023686A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2382474A1 (en) | 2011-11-02 |
| EP2382474B1 (en) | 2015-03-04 |
| JP5379243B2 (ja) | 2013-12-25 |
| ZA201105271B (en) | 2012-03-28 |
| TW201031917A (en) | 2010-09-01 |
| RU2011134415A (ru) | 2013-02-27 |
| SG173065A1 (en) | 2011-08-29 |
| CN102292638B (zh) | 2014-05-28 |
| IL213098A0 (en) | 2011-07-31 |
| PT2382474E (pt) | 2015-06-03 |
| MX2011007386A (es) | 2011-08-03 |
| HUE025015T2 (en) | 2016-04-28 |
| TWI440854B (zh) | 2014-06-11 |
| US20110312525A1 (en) | 2011-12-22 |
| HRP20150470T1 (hr) | 2015-06-05 |
| KR20110116016A (ko) | 2011-10-24 |
| JP2012515893A (ja) | 2012-07-12 |
| AU2010206195B2 (en) | 2016-03-10 |
| CR20110438A (es) | 2011-12-28 |
| NZ593749A (en) | 2012-05-25 |
| SG196837A1 (en) | 2014-02-13 |
| HK1161643A1 (en) | 2012-07-27 |
| ES2536747T3 (es) | 2015-05-28 |
| US20140023686A1 (en) | 2014-01-23 |
| AU2010206195A1 (en) | 2010-07-29 |
| CA2749192A1 (en) | 2010-07-29 |
| CN102292638A (zh) | 2011-12-21 |
| PL2382474T3 (pl) | 2015-08-31 |
| WO2010084100A1 (en) | 2010-07-29 |
| DK2382474T3 (en) | 2015-04-07 |
| IL213098A (en) | 2015-08-31 |
| CO6390020A2 (es) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0906261A2 (pt) | "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente" | |
| BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
| IT1406051B1 (it) | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. | |
| BRPI1011316A2 (pt) | aparelho e método para administrar uma substância ao tecido da pele, método para tratar um indivíduo tendo uma condição de pele, e, kit | |
| BRPI0807927A2 (pt) | Métodos para determinar uma susceptibilidade a doença cardiovascular em um indivíduo humano, de identificação de um marcador para uso para avaliar susceptibilidade a doença cardiovascular, para genotipar uma amostra de ácido nucleico, para avaliar um indivíduo para probabilidade de resposta a um agente terapêutico, para predizer prognóstico de um indivíduo diagnosticado com doença cardiovascular, e para monitorar progresso de tratamento de um indivíduo passando por tratamento para doença cardiovascular, kit para avaliar susceptibilidade a doença cardiovascular em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para doença cardiovascular em um indivíduo humano | |
| BRPI0906903A2 (pt) | ''anticorpo kit de diagnóstico, método de detecção da expressão de cd70 em uma amostra de tecido, método para prognosticar, determinar um protocolo de tratamento ou monitorar o tratamento, uso de um agente de ligação a cd70 e combinação de um kit de diagnóstico e um kit farmacêutico | |
| BRPI0916269A2 (pt) | dispositivo de modificação de tecido e seu método de uso | |
| BRPI0910010A2 (pt) | dispositivo para uso na retração de uma gengiva de um dente humano, método de retração da gengiva de um dente humano e kit de peças | |
| BRPI1009346A2 (pt) | metodo de formacao de imagem optica in vivo das margens tumorais de um tumor, agente de contraste, composicao farmaceutica, e, kit | |
| GB2462764B (en) | Ex vivo methods for validating substance testing with human organs and or tissues | |
| BRPI1009847A2 (pt) | conectores médicos e métodos de uso | |
| BRPI1010304A2 (pt) | dispositivo de espectroscopia óptica para detecção de glicose no sangue não invasiva e método de uso associado. | |
| BR112013019083A2 (pt) | combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença. | |
| EP2310039A4 (en) | FGF-9 AND ITS APPLICATION IN CONNECTION WITH BLOOD VESSELS | |
| PT2252283T (pt) | Triterpenóides sintéticos e métodos de uso no tratamento de doença | |
| PT2257155T (pt) | Criopreservação de células e tecidos biológicos | |
| BRPI0910852A2 (pt) | composições contendo lipídios e métodos de uso das mesmas | |
| BR112012030576A2 (pt) | aparelho de medição de analito do tecido e método para medir um analito de tecido de um paciente | |
| IL212856A (en) | Human antibodies against human tissue factor, conjugates and uses thereof | |
| BRPI0912292A2 (pt) | composições e métodos para o uso de células no tratamento do tecido cardíaco. | |
| BRPI1006733A2 (pt) | kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método | |
| EP2298365A4 (en) | MEDICAL COMPOSITION AND MEDICAL KIT | |
| BRPI0919560A2 (pt) | dispositivo para tratamento extracorpóreo do sangue no modo de operação de agulha única e método para a operação de um dispositivo para o tratamento extracorpóreo do sangue | |
| BRPI0909563A2 (pt) | biomaterial, método de produção do biomaterial, uso do biomaterial e mpetodo de tratamento de lesões de tecidos em pacientes | |
| BRPI1006901A2 (pt) | método ex vivo e kit para testar se um paciente responderá terapeuticamente a um método de tratamento, e, uso de níveis de sicam-1 em uma amostra de sangue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2467 DE 17/04/2018 POR TER SIDO INDEVIDA. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |